Inflammatory burden in adolescents with prolonged parent-child separation

Liu, Wanxu; Zhang, Anhui; He, Haiyan; Zhao, Xudong; Tao, Fangbiao; Sun, Ying

doi:10.1016/j.bbi.2021.08.227

Cited by 9 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results need to be validated and tested in other and larger cohorts. Recently, a study of 574 adolescents reported similar findings, showing that persistent parent-child separation was more frequently observed among individuals with high suPAR and low CRP or with high suPAR and high CRP, compared to individuals with low suPAR and low or high CRP ( 165 ).…”

Section: Properties and Characteristics Indicating That Supar Is A Marker Of Scimentioning

confidence: 69%

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation

2021

View full text Add to dashboard Cite

Systemic chronic inflammation (SCI) is persistent, health-damaging, low-grade inflammation that plays a major role in immunosenescence and in development and progression of many diseases. But currently, there are no recognized standard biomarkers to assess SCI levels alone, and SCI is typically measured by combining biomarkers of acute inflammation and infection, e.g., CRP, IL-6, and TNFα. In this review, we highlight 10 properties and characteristics that are shared by the blood protein soluble urokinase plasminogen activator receptor (suPAR) and SCI, supporting the argument that suPAR is a biomarker of SCI: (1) Expression and release of suPAR is upregulated by immune activation; (2) uPAR and suPAR exert pro-inflammatory functions; (3) suPAR is associated with the amount of circulating immune cells; (4) Blood suPAR levels correlate with the levels of established inflammatory biomarkers; (5) suPAR is minimally affected by acute changes and short-term influences, in contrast to many currently used markers of systemic inflammation; (6) Like SCI, suPAR is non-specifically associated with multiple diseases; (7) suPAR and SCI both predict morbidity and mortality; (8) suPAR and SCI share the same risk factors; (9) suPAR is associated with risk factors and outcomes of inflammation above and beyond other inflammatory biomarkers; (10) The suPAR level can be reduced by anti-inflammatory interventions and treatment of disease. Assessing SCI has the potential to inform risk for morbidity and mortality. Blood suPAR is a newer biomarker which may, in fact, be a biomarker of SCI since it is stably associated with inflammation and immune activation; shares the same risk factors as many age-related diseases; is both elevated by and predicts age-related diseases. There is strong evidence that suPAR is a prognostic marker of adverse events, morbidity, and mortality. It is associated with immune activity and prognosis across diverse conditions, including kidney disease, cardiovascular disease, cancer, diabetes, and inflammatory disorders. Thus, we think it likely represents a common underlying disease-process shared by many diseases; that is, SCI. We review the supporting literature and propose a research agenda that can help test the hypothesis that suPAR indexes SCI, with the potential of becoming the new gold standard for measuring SCI.

show abstract

Section: Properties and Characteristics Indicating That Supar Is A Marker Of Scimentioning

confidence: 69%

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation

2021

View full text Add to dashboard Cite

show abstract

“…In another study, neuronal development and maturation in the hippocampus were impaired in female offspring with long maternal separation, leading to deficits in learning and memory, whereas neuronal development was normal in offspring with brief maternal separation [ 48 ]. A clinical study also showed that children who were separated from their mothers for a long period of time had an increased burden of inflammation and a higher risk of psychiatric disease [ 49 ].…”

Section: Discussionmentioning

confidence: 99%

Brief Maternal Separation Promotes Resilience to Anxiety-like and Depressive-like Behaviors in Female C57BL/6J Offspring with Imiquimod-Induced Psoriasis

Zhou

et al. 2022

Brain Sciences

View full text Add to dashboard Cite

Background: Psoriasis is a common chronic inflammatory skin disease that often causes depression. Early life experience affects brain development and relates to depression. Whether the effect of different MS protocols in early life on anxiety-like and depressive-like behaviors in female offspring with imiquimod (IMQ)-induced psoriasis is unknown. Methods: C57BL/6J mice were subjected to no separation (NMS), brief MS (15 min/day, MS15) or long MS (180 min/day, MS180) from postpartum days (PPD) 1 to PPD21. Then, 5% imiquimod cream was applied for 8 days in adults. Behavioral tests, skin lesions and hippocampal protein expression were also assessed. Results: We found significant psoriasis-like skin lesions in female mice following IMQ application, and mice showed anxiety-like and depressive-like behaviors. Further, increased microglial activation and decreased expression of neuroplasticity were detected in mice following IMQ application. However, after MS15 in early life, mice showed decreased anxiety-like and depressive-like behaviors, indicating resilience. Further, inhibited hippocampal neuroinflammation and increased neuroplasticity were detected. Conclusions: Collectively, this study confirms that brief MS confers resilience to the behavior deficits in female offspring with IMQ-induced psoriasis and reverses the activation of neuroinflammation and the damage of neuroplasticity injury.

show abstract

“…[92] Parent-child separation 574 adolescents were evaluated. Persistent parent-child separation experiences led to significantly increased biomarkers of inflammation Increased inflammatory burden [93] Multi-hit early life events This is a rodent study using C3H/HeN mice of both sexes. Sex-specific effects in the adults were evident.…”

Section: Coronary Heart Disease [70]mentioning

confidence: 99%

Using Microbiome-Based Approaches to Deprogram Chronic Disorders and Extend the Healthspan following Adverse Childhood Experiences

Dietert

Dietert²

2022

Microorganisms

View full text Add to dashboard Cite

Adverse childhood experiences (ACEs), which can include child trafficking, are known to program children for disrupted biological cycles, premature aging, microbiome dysbiosis, immune-inflammatory misregulation, and chronic disease multimorbidity. To date, the microbiome has not been a major focus of deprogramming efforts despite its emerging role in every aspect of ACE-related dysbiosis and dysfunction. This article examines: (1) the utility of incorporating microorganism-based, anti-aging approaches to combat ACE-programmed chronic diseases (also known as noncommunicable diseases and conditions, NCDs) and (2) microbiome regulation of core systems biology cycles that affect NCD comorbid risk. In this review, microbiota influence over three key cyclic rhythms (circadian cycles, the sleep cycle, and the lifespan/longevity cycle) as well as tissue inflammation and oxidative stress are discussed as an opportunity to deprogram ACE-driven chronic disorders. Microbiota, particularly those in the gut, have been shown to affect host–microbe interactions regulating the circadian clock, sleep quality, as well as immune function/senescence, and regulation of tissue inflammation. The microimmunosome is one of several systems biology targets of gut microbiota regulation. Furthermore, correcting misregulated inflammation and increased oxidative stress is key to protecting telomere length and lifespan/longevity and extending what has become known as the healthspan. This review article concludes that to reverse the tragedy of ACE-programmed NCDs and premature aging, managing the human holobiont microbiome should become a routine part of healthcare and preventative medicine across the life course.

show abstract

Inflammatory burden in adolescents with prolonged parent-child separation

Cited by 9 publications

References 33 publications

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation

Brief Maternal Separation Promotes Resilience to Anxiety-like and Depressive-like Behaviors in Female C57BL/6J Offspring with Imiquimod-Induced Psoriasis

Using Microbiome-Based Approaches to Deprogram Chronic Disorders and Extend the Healthspan following Adverse Childhood Experiences

Contact Info

Product

Resources

About